ArticleBiosensors2025
A Microfluidic Chip-Based Integrated Device Combining Aerosol Sampling and LAMP-CRISPR Detection for Airborne Virus Surveillance.
Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Detecting airborne viruses using an integrated aerosol sampling detection device is of great significance in epidemic prevention and control. Most of the applicable aerosol samplers have a flow rate of less than 1000 L/min, which is insufficient for application in large public spaces. Recent research, on the other hand, has revealed the advantages of microfluidic chip-based LAMP-CRISPR in airborne virus detection; however, this promising detection method has yet to be integrated with an aerosol sampler. Herein, we present an aerosol sampling and microfluidic chip-based detection (ASMD) device that couples a high-flow-rate aerosol sampling (HFAS) system with a microfluidic LAMP-CRISPR detection (MLCD) chip for surveilling airborne viruses, as represented by SARS-CoV-2. The HFAS system achieved a 6912 L/min flow rate while retaining a satisfactory collection efficiency, and achieved an enrichment ratio of 1.93 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.